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Summary   
Objective: To perform a comparative assessment of tolerability of all licensed new antiepileptic 
drugs (AEDs) through a network meta-analysis (NMA) including all placebo-controlled double-
blind clinical trials  (RCTs) in all conditions in which these drugs have been tested. 
Methods: NMA with a frequentist approach was used to compare proportions of patients 
withdrawing because of adverse events (AEs). Analyses were conducted for all therapeutic doses 
pooled and specifically for high therapeutic doses. Patients treated with non-therapeutic doses of 
each drug were excluded. 
Results: A total of 195 RCTs were included in the current analysis,  comprising a  
total of 28013 patients treated with AEDs and 17908 patients treated with placebo. RCTs included 
in the analysis were 8 for  brivaracetam, 5 for eslicarbazepine, 22 for gabapentin,  7 for lacosamide, 
14 for levetiracetam, 14 for lamotrigine, 6 for oxcarbazepine, 9 for perampanel, 50 for pregabalin, 5 
for tiagabine, 36 for topiramate, 7 for zonisamide, 4 for gabapentin-extended formulation (ER), 2 
each for levetiracetam-ER, lamotrigine-ER, topiramate-ER, and 1 each for oxcarbazepine-ER and 
pregabalin-ER. 
Brivaracetam, gabapentin, gabapentin-ER, and levetiracetam had a significantly lower withdrawal 
rate compared to several other AEDs, while eslicarbazepine, lacosamide, oxcarbazepine, and 
topiramate had a higher withdrawal rate. Perampanel, lamotrigine, pregabalin, tiagabine, and 
zonisamide showed an intermediate pattern of tolerability.   
Additional analysis has been conducted through selection of highly recommended doses for each 
drug. This analysis has roughly confirmed results of head to head comparisons of the all dose 
analysis, with some exceptions. A further analysis has been conducted after exclusion of RCTs in 
which patients were allocated to the therapeutic dose of the experimental drug without titration and 
it failed to show clinically important differences. 
Significance: Relevant differences in short-term tolerability of AEDs have been observed between 
AEDs. Brivaracetam, gabapentin and levetiracetam, show the best tolerability profile while other 
AEDs are at higher risk for intolerable adverse effects.  
 
 
Key words: meta-analysis, network meta-analysis, adverse effects, tolerability of antiepileptic 
drugs, brivaracetam, perampanel, eslicarbazepine, lacosamide 
  
 1. Introduction   
In recent years, several new antiepileptic drugs (AEDs) have been approved as add-on treatments in 
drug-resistant focal epilepsy patients (1-2). Although information on comparative efficacy and 
tolerability of these drugs is of strategic importance for the choice of the appropriate AED, 
registrative, double-blind, placebo-controlled studies do not give this information (1,3).  
Recently a new meta-analytical technique, the so-called network meta-analysis (NMA), has been 
proposed as an objective way of comparing alternative treatments where direct treatment 
comparisons are not available (4,5). Up to now, several NMAs of efficacy and tolerability of AEDs 
including RCTs performed in patients with drug-resistant focal epilepsy, provided different 
conclusions (6-11). 
In this meta-analysis, assessment of short-term tolerability of all new AEDs has been performed 
trough a NMA aimed at comparing the most robust outcome measure of tolerability (patients 
withdrawing because of adverse effects) in all double-blind, placebo-controlled RCTs performed in 
adults in which these drugs have been tested, including those performed in conditions other than 
epilepsy. The number of patients withdrawing because of adverse effects is not influenced by all 
sources of heterogeneity which hamper analysis of efficacy (11,12). Analyses were performed both 
for all doses pooled and specifically for high doses. A further analysis was conducted to assess the 
relative weight of titration rate.  
   
 
2.0 Methods 
 
We performed a systematic review of all placebo-controlled, double-blind RCTs assessing the use 
of licensed AEDs in all conditions in which these drugs have been studied in adults. 
The following drugs have been included in the analysis: brivaracetam (BRV), eslicarbazepine 
(ESL), gabapentin (GBP), lacosamide (LCM), lamotrigine (LTG), levetiracetam (LEV), 
oxcarbazepine (OXC), perampanel (PER), pregabalin (PGB), tiagabine (TGB), topiramate (TPM), 
zonisamide (ZNS). Extended release (ER) formulations of AEDs were considered as different 
AEDs and were included in the analysis, even though some of them are not yet available in the 
clinical practice. 
Studies were identified through MEDLINE (PubMED interface) and EMBASE up to April 2016. 
This study was done according to the preferred reporting items for systematic reviews and meta-
analyses guidelines (13). See PRISMA checklist in S1. 
  
2.1 Eligibility criteria 
All double-blind placebo-controlled RCTs exploring efficacy of the above cited AEDs in any 
condition they have been studied and reporting patients withdrawing because of  adverse events 
(AEs) as an outcome, with a parallel or cross-over design, and a duration of double-blind phase of 
at least 4 weeks, were included. For details of inclusion/exclusion criteria, see S2.   
 
2.2 Data abstraction 
For each RCT two authors assessed eligibility and risk of bias, and extracted data. Cochrane 
Collaboration’s tool for assessing risk of bias (14) was used to ascertain the validity of eligible 
RCTs. For each study, number of patients treated with placebo, and with the active drug at different 
doses, and the number of patients withdrawing because of AEs in all study arms, were extracted.  
 
2.3 Data analysis 
NMA with a frequentist approach was used to compare proportions of patients withdrawing because 
of AEs while on treatment, using the netmeta R package version 8.0 (available at: http://CRAN.R-
project.org/package=netmeta) to calculate point estimates of odds ratios (ORs) with 95% 
confidence intervals (CIs) and generate head-to-head comparison and forest plots using random-or 
fixed-effect model comparing the effect estimates of different AEDs relative to placebo (15). P rank 
scores were generated to determine probability scores to rank which AEDs result in the lowest 
proportion of withdrawals due to AEs. Heterogeneity across individual studies was assessed by 
using the Cochran Q (Chi-squared) and Higgins I2 statistics which quantified the percent of total 
variation due to between study heterogeneity (16). As the heterogeneity among studies was low (see 
results), data were analysed using a fixed-effect model. 
 
For each AED, all these analyses have been performed after the exclusion of studies or arms of 
studies in which patients were treated with doses outside the range of therapeutic doses. These were 
doses which, according to the summary product characteristics (SPC) (17) of each drug, were under 
the therapeutic dose or above the high therapeutic dose. For some AEDs, these doses are not clearly 
specified in the SPC. In such cases doses were considered as not  therapeutic when these were 
found not significantly effective in pivotal RCTs of drug-resistant epilepsy.   
For the ER formulations, we considered that therapeutic doses were the same as for the immediate-
release formulations (see table 1 in S2).  
Two analyses have been performed. In the first analysis all patients treated with a drug dose within 
the range of effective doses were summed (“All dose analysis”). A secondary analysis was 
restricted to studies or arms of studies in which patients were treated with the highest of 
recommended doses according to the SPC (“High dose analysis”).  
Finally, further secondary analyses were performed excluding patients who received full 
maintenance doses without prior titration (all dose analysis and high dose analysis after the 
exclusion of studies or arms of studies in which patients were randomized to the active treatment 
without titration) . 
 
 
3.0 Results 
 
3.1 Characteristics of eligible trials 
Flow charts of the identified studies and relative references are reported for each AED in 
supplementary material S3.  
From 231 RCTs, after exclusion of RCTs exploring only doses not included in the range of 
therapeutic doses (n=36), a total of 195 RCTs were included in the analysis (8 for BRV, 5 for ESL, 
22 for GBP, 7 for LCM, 14 for LEV, 14 for LTG, 6 for OXC, 9 for PER, 50 for PGB, 5 for TGB, 
36 for TPM, 7 for ZNS). Six AED had corresponding ER formulations. These were GBP (four 
studies), LEV, LTG and TPM (two studies each), and OXC and PGB (one study each). The main 
features of the 195 RCTs included in the analysis are reported in S4. AEDs were explored in several 
diseases which have been grouped in seven main conditions (epilepsy, pain, movement disorders, 
obesity and binge eating disorders, psychiatric disorders, substance abuse, and miscellanea) (See 
S5). 
A total of 28013 patients were treated with therapeutic drug doses of experimental drugs and  were 
included in the analysis with 17908 placebo-treated patients. For each drug the number of patients 
treated with the experimental drug and with placebo were, respectively: 1369 and 722 for BRV, 
1086 and 560 for ESL, 2587 and 1958 for GBP, 847 and 394 for GBP –ER, 1401 and 655 for LCM, 
1089 and 805 for LEV, 116 and 116 for LEV-ER, 1277 and 84 for LTG, 199 and 197 LTG-ER, 854 
and 523 for OXC, 122 and 121 for OXC-ER, 1794 and 1203 for PER, 8110 and 5175 for PGB, 113 
and 110 for PGB –ER, 1011 and 637 for TGB, 5239 and 3228 for TPM, 178 and 182 for TPM-ER, 
and 623 and 472 for ZNS. Twenty RCTs were cross over studies and for these studies both phases 
of the study were considered. Network geometry is given in fig. 1. 
Sample size of patients treated with the active drug and with placebo varied across trials from a 
minimum of 20 and 16 patients, respectively, to a maximum of 680 and 261 patients.  
Mean duration of all double-blind period (titration plus maintenance) (mean ± SD) was 13.9 ± 8.4 
weeks (range 4–60). The duration of the titration period was also highly variable among all RCTs 
(from no titration up to 16 weeks). 
Most of the trials had a low risk of bias (see  S6). 
 
3.2. Quantitative data synthesis 
A total of 18 pairwise comparisons were available for each AED for all dose analysis and 14 for the 
high dose analysis. For three extended release formulations (LTG-ER, PGB-ER and TPM-ER), 
there were no data for the high dose analysis. For LTG it was not possible to isolate patients treated 
with high doses and  only the all dose analysis  has been performed. (See fig 2). 
It was found that all ER formulations do not show a significant difference in respect to placebo, 
both with the all dose analysis and with the high dose analysis. This finding, with the exception of 
GBP-ER, was likely to be related to  their  wide CIs. Also BRV, both at all doses and at high doses, 
and LEV, only at high doses, did not show significant differences compared with  placebo. All other 
AEDs showed a significantly lower tolerability compared to placebo. Increased OR values  for the 
high dose analysis in respect to full dose analysis were found for ESL, LCM, OXC, PER, PGB, 
TPM, and ZNS.   
Head-to-head comparisons both for all dose analyses and  for high dose analyses is shown in S7.  
In table I only those comparisons which displayed significant findings are  indicated for each AED. 
It is shown that BRV, GBP, GBP-ER, and LEV have a significantly lower withdrawal rate 
compared with several other drugs, while ESL, LCM, OXC, and TPM showed a worse 
performance. Perampanel, LTG, PGB, TGB and ZNS show an intermediate pattern of tolerability. 
Non-significant findings were observed for head-to-head comparisons of all ER formulations (with 
the exception of GBP-ER) and this was likely due to the wide CI. 
    Rank analysis, which indicates the probability score that a drug is associated to the lowest 
withdrawal  rate, is shown in Figure 3 both for all doses analysis and for high dose analysis.  
Finally, we performed a further analysis excluding those studies or arms of studies in which patients 
were randomized without titration. This study design was adopted with 7 AEDs for a total of 25 
RCTs. In 5 of these studies the experimental drug was BRV, in 9 it was GBP, in 1 LEV, 1 LEV-ER, 
1 PER, 7 PGB and 1 ZNS. Briefly, with this analysis LEV tolerability was slightly further improved 
and this drug appeared significantly better tolerated not only as compared with ESL and OXC (as 
shown in the general all doses analysis above reported) but also in comparison with TPM. In the 
case of BRV, IC become very wide and all findings related to this drug became non-significant. 
Also in the case of PER, wider IC caused the loss of a significant better profile of PER in respect to 
ESL at high doses. For the AEDs PGB, GBP, LEV-ER and ZNS, no changes were observed 
compared with the general all doses analysis above reported. Detailed data are reported in S8. 
There was no significant heterogeneity/inconsistency among comparisons investigated. Namely I2 
of the proportions was 9.5% (Q = 185.5; p value = 0.168) for all doses and 16.9% (Q = 138.4; p 
value = 0.067) for high doses analyses. 
 
 
4. Discussion  
 
This analysis of comparative tolerability of 18 new AEDs has assessed the number of patients 
withdrawing because of AEs, which is considered a robust tolerability outcome measure,  in a 
population of almost 46.000 patients recruited in 195 RCTs and several, significant and consistent 
findings have been detected (see figure 2, table I and S7). Figure 3 shows that drug tolerability has a 
probability score of being associated with the lowest withdrawal rate (placebo) which ranges from 
about 80% for GBP, to about 10% for OXC.  
Several previous NMA, performed with the aim to compare both efficacy and tolerability of AEDs 
used as add on drugs in focal epilepsies, came to non-significant or contradictory results (6-9).  
There are several factors which have limited the validity of these analyses (10). These are the small 
number of subjects which are often included in the meta-analyses, with consequent wide confidence 
intervals and lack of significant results and, most importantly, the heterogeneity of casistics and 
methods of analysis of efficacy data among different RCTs (10,11). However, some heterogeneity 
sources which limit  validity of assessment of efficacy do not apply to the assessment of tolerability 
(10,11,). In fact, date of publication (11,12,18) and different techniques of analysis  (last 
observation carried forward  analysis) (11) heavily influence the assessment of efficacy, while they 
do not affect withdrawal rate (11,12). 
Furthermore, analysis of AEDs tolerability may be easier to accomplish and can be conducted in a 
wider population of patients since also studies in conditions different from epilepsy can be included 
(19,20).  
 
Three critical points may affect results of this comparative analysis.  
The first point is related to the AED dose. It is known that short term adverse events, which may 
lead to drug withdrawal, are critically influenced by dose (19,20,21,22). Therefore, equieffective 
doses of drugs should be compared. Unfortunately, equieffective doses of AEDs are unknown; 
furthermore, in several RCTs, they have been tested also at doses which are now considered as 
ineffective or higher than the range of effective doses. For this reason, we excluded from our 
analysis doses outside the range of therapeutic doses. Results of full dose analysis show that BRV, 
GBP, GBP-ER, LEV, LTG, PER and ZNS were significantly better tolerated than one or more of 
the remaining AEDs, while ESL, LCM, OXC, PGB, and TPM showed a significantly worse 
tolerability compared to other drugs. TGB was neither better nor worse than other AEDs.  
To explore the specific role of high doses in inducing intolerable adverse events, a further analysis 
has been performed only with high recommended doses. A worsened tolerability was observed with 
the high dose analysis for the AEDs ESL, PER, LCM and OXC and, to a lesser degree, for ZNS, 
PGB, and TPM (figure 2 and figure 3). Tolerability of BRV and GBP was not apparently influenced 
by the dose. In the case of LEV, an apparent mild improvement of tolerability at high doses, 
confirms a lack of a dose-effect relationship for the adverse effects of this drug (23). From a general 
point of view, results of these analyses  show that, although drug tolerability is often worsened at 
high doses, this dose-effect does not have a major impact in the overall picture of relative 
comparability of AEDs. It seems that drug tolerability, within the range of therapeutic doses, is 
more dependent on the selected drug than on drug dose.   
A second critical point is titration. Several studies show that titration speed may have a relevant role 
for the appearance of dose-dependent adverse events  (19,20,21,22,24,25,26). However, titration 
speeds were very different in the different selected RCTs and we could only assess the effect of 
titration excluding studies or arms of studies in which patients were randomized without any 
titration. In this sub-analysis, LEV tolerability resulted mildly improved, while for the other 6 
AEDs which had RCTs excluded from the analysis, no changes (GBP, LEV-ER, PGB, ZNS) or 
inconsistent results (BRV, PER) were found, mainly because of wider ICs (see S 8).   
It can be speculated that titration in RCTs is set at different speeds which depend on the 
characteristics of each drug (as assessed in phase 1 and 2 studies) and represents a compromise 
between the need to minimize intolerable AEs and that of avoiding unnecessary long double-blind 
periods.  
A third critical point is represented by the fact that drug tolerability in RCTs can be affected by 
several factors unrelated to the experimental drug, such as tolerability of background treatments (in 
add on studies), the disease for which these drugs have been studied, and different times and 
geographical areas in which studies have been done (12,27). However, although some of these 
factors have a major impact on efficacy, tolerability seems to be less influenced by them. In fact, in 
a meta-analysis of all double-blind RCTs conducted in patients with focal epilepsy,  proportions of 
placebo-treated patients withdrawing because of adverse effects was only mildly influenced by the 
condition explored (27). A further meta-analysis of all double-blind studies performed with PGB, 
showed that risk difference of patients who withdrew because of adverse effects was not affected by 
the condition explored (28). In the case of other AEDs,  concomitant treatments may influence 
tolerability as it has been shown with LCM (29). Finally, we cannot exclude that efficacy of the 
experimental agent in a specific condition may influence tolerability, since patients experiencing no 
or marginal improvements would be more prone to find their AEs as intolerable. 
 
As regards ER formulations of six AEDs, due to the small number of patients recruited, no 
significant findings were observed for any of these AEDs with the exception of GBP-ER which had 
an excellent tolerability, very similar to that of its immediate-release formulation.   
 
In conclusion,  this comparative meta-analysis constitutes an objective assessment of relative short-
term tolerability of AEDs. It is known that frequency and severity of drug-related adverse effects 
are influenced both by biological and by psychological factors and that their assessment is highly 
dependent on the clinical and/or experimental setting (12). Therefore, these effects can be precisely 
assessed only in placebo-controlled studies and, due to the lack of large comparative controlled 
studies, this indirect comparison may constitute the only way to approach the problem. It can be 
expected that, for each of the AEDs tested, different percentages of patients treated with high or 
therapeutic doses, different percentages of patients randomised to optimal or suboptimal speed 
titrations, and finally different percentages of patients with different conditions or concomitant 
treatments, may have influenced  results of this comparative analysis. However we are convinced 
these aspects cannot offset the detected differences in short-term tolerability between these AEDs.  
BRV, GBP and LEV, show the best tolerability profile while other AEDs are at higher risk for 
intolerable adverse effects. Incidentally, those AEDs which had a better tolerability profile (BRV 
and GBP) were also those for which no titration had been adopted in several of their studies, which 
is consistent with their excellent tolerability pattern.  
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Table I 
Antiepileptic 
drug 
Analysis Significantly better than Significantly worse than 
Brivaracetam All doses  eslicarbazepine, oxcarbazepine, 
topiramate 
 
 High 
doses 
eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
Eslicarbazepine All doses   gabapentin, gabapentin-er, 
perampanel  
 High 
doses 
 brivaracetam, gabapentin, 
gabapentin-er, levetiracetam, 
perampanel, tiagabine 
Gabapentin All doses  eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
 High 
doses 
eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
Gabapentin-
ER 
All doses  eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
 High 
doses 
eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
Lacosamide All doses   gabapentin, gabapentin- ER  
 High 
doses 
 brivaracetam, gabapentin, 
gabapentin-er, levetiracetam,  
Levetiracetam All doses  eslicarbazepine, oxcarbazepine  
 High 
doses 
eslicarbazepine, lacosamide, 
oxcarbazepine, pregabalin, 
topiramate 
 
Lamotrigine All doses  oxcarbazepine  
    
Oxcarbazepine All doses   brivaracetam, gabapentin, 
gabapentin-ER, levetiracetam, 
lamotrigine, perampanel, 
zonisamide  
 High 
doses 
 brivaracetam, gabapentin, 
gabapentin-ER, levetiracetam, 
perampanel, pregabalin, tiagabine, 
zonisamide 
Perampanel All doses  eslicarbazepine, oxcarbazepine,  
pregabalin, topiramate 
 
 High 
doses 
eslicarbazepine, oxcarbazepine,  
Pregabalin All doses   gabapentin, gabapentin-ER, 
perampanel 
 High 
doses 
oxcarbazepine, brivaracetam, gabapentin, 
gabapentin-ER, levetiracetam,  
Tiagabine All doses    
 High 
doses 
eslicarbazepine, oxcarbazepine,  
Topiramate All doses   brivaracetam, gabapentin, 
gabapentin-er, perampanel 
 High 
doses 
 brivaracetam, gabapentin, 
gabapentin-ER, levetiracetam, 
Zonisamide All doses  oxcarbazepine,  
 High 
doses 
oxcarbazepine  
 
  
  
 
Legend:  
Figure 1 Network configuration. The greater is the line thickness the higher is the evidence (i.e. 
number of studies, number of patients). 
Figure 2: Funnel plot. Odd ratio (OR) with 95% confidence intervals (ICs) of all comparisons of 
each antiepileptic drug with placebo.  
Figure 3: P rank scores of all assessed antiepileptic drugs. P rank scores indicate the probability 
scores to rank which treatments result associated to the lowest withdrawal rate  
Table: Summary of most important findings of this meta-analysis. For each AED, only significant 
results of each comparison with all other antiepileptic drugs are reported. For explanation, see text 
 
  
  
 Supporting Information 
Additional Supporting Information may be found in the online version of this article: 
 
S1:  PRISMA checklist  
S2: Inclusion and exclusion criteria and therapeutic doses included in the analysis for each AED. 
S3: Flow charts and references of the identified studies 
S4: Main features of the 196 RCTs included in the analysis 
S5: Diseases explored and main conditions in which they were grouped 
S6: Risk of bias of the included studies  
S7: Results of main findings  
S8: Results of secondary analyses     
 
